EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
EyePoint (NASDAQ: EYPT) granted inducement non‑statutory stock options to three new employees to purchase an aggregate of 13,500 shares, effective October 15, 2025, in accordance with NASDAQ Listing Rule 5635(c)(4).
The options carry an exercise price of $11.73 (closing price on October 15, 2025), a 10‑year term, and vest over four years (25% after one year, then monthly over three years), subject to continued service. Grants were approved by the Compensation Committee as inducements for new hires.
EyePoint (NASDAQ: EYPT) ha concesso opzioni azionarie non statutarie di inducement a tre nuovi dipendenti per acquistare un complessivo 13.500 azioni, con efficacia 15 ottobre 2025, in conformità con NASDAQ Listing Rule 5635(c)(4).
Le opzioni hanno un prezzo di esercizio di 11,73 USD (prezzo di chiusura al 15 ottobre 2025), una durata di 10 anni e vestono nel corso di quattro anni (25% dopo un anno, poi mensilmente nel corso dei tre anni successivi), soggette a continuativa prestazione di servizio. Le assegnazioni sono state approvate dal Compensation Committee come inducimenti per i nuovi assunti.
EyePoint (NASDAQ: EYPT) concedió opciones sobre acciones de inducement no estatutarias a tres nuevos empleados para comprar un total de 13.500 acciones, con efecto a partir del 15 de octubre de 2025, de acuerdo con NASDAQ Listing Rule 5635(c)(4).
Las opciones tienen un precio de ejercicio de 11,73 USD (precio de cierre al 15 de octubre de 2025), un plazo de 10 años y se consolidan durante cuatro años (25% tras un año, y luego mensualmente durante los tres años siguientes), sujeto a la continuidad del servicio. Las adjudicaciones fueron aprobadas por el Comité de Compensación como incentivos para las nuevas contrataciones.
EyePoint (NASDAQ: EYPT)가 세 명의 신입 직원에게 총 13,500주의 inducement 비상장 주식 옵션을 부여하여 2025년 10월 15일 부터 효력을 발휘하며, NASDAQ Listing Rule 5635(c)(4)에 따라 이루어졌습니다.
옵션의 행사 가격은 11.73달러이며(2025년 10월 15일 종가), 기간은 10년이고, 4년에 걸쳐 vest됩니다(1년 후 25%, 이후 3년간 매월 vesting), 지속적인 근무를 조건으로 합니다. 이번 부여는 신규 채용자에 대한 인센티브로 보상 위원회가 승인했습니다.
EyePoint (NASDAQ: EYPT) a accordé des options d'achat d'actions non statutaires d'incitation à trois nouveaux employés pour acheter un total de 13 500 actions, effectif à partir du 15 octobre 2025, conformément à NASDAQ Listing Rule 5635(c)(4).
Les options comportent un prix d'exercice de 11,73 USD (cours de clôture au 15 octobre 2025), une durée de 10 ans et se vestent sur quatre ans (3 ¼ après un an, puis mensuellement sur les trois années suivantes), sous réserve d'un service continu. Les attributions ont été approuvées par le Comité de rémunération comme incitations pour les nouvelles embauches.
EyePoint (NASDAQ: EYPT) hat inducement Non-Statutory Stock Options an drei neue Mitarbeiter gewährt, um insgesamt 13.500 Aktien zu erwerben, wirksam ab dem 15. Oktober 2025, gemäß NASDAQ Listing Rule 5635(c)(4).
Die Optionen haben einen Ausübungspreis von 11,73 USD (Schlusskurs am 15. Oktober 2025), eine Laufzeit von 10 Jahren und vesten über vier Jahre (25% nach einem Jahr, danach monatlich über drei Jahre), vorbehaltlich fortgesetzter Dienstleistung. Die Zuteilungen wurden vom Vergütungsausschuss als Anreize für neueinstellungen genehmigt.
EyePoint (NASDAQ: EYPT) منح خيارات أسهم حافزة غير تشريعية لثلاثة موظفين جدد لشراء إجمالي 13,500 سهم، سارية اعتباراً من 15 أكتوبر 2025، وفقاً لـ قواعد إدراج ناسداك 5635(c)(4).
تحتوي الخيارات على سعر ممارسة قدره 11.73 دولاراً (سعر الإغلاق في 15 أكتوبر 2025)، مدة عشر سنوات، وتتحقق على مدى أربع سنوات (25% بعد عام واحد، ثم شهرياً خلال الثلاث سنوات التالية)، رهناً باستمرار الخدمة. تمت الموافقة على المنح من قبل لجنة التعويضات كحوافز للتوظيفات الجديدة.
EyePoint (NASDAQ: EYPT) 已向三名新员工授予诱导性非法定股票期权，用于购买合计 13,500 股，自 2025 年 10 月 15 日起生效，符合 NASDAQ Listing Rule 5635(c)(4)。
期权的行权价为 11.73 美元（2025 年 10 月 15 日收盘价），期限为 10 年，并在 四年内逐步生效（第一年后 25%，随后在三年内按月 vest），前提是持续服务。授予经薪酬委员会批准，作为新员工的诱因。
- None.
- None.
WATERTOWN, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
The Company granted stock options to purchase up to an aggregate of 13,500 shares of EyePoint common stock to three new employees. The stock options were granted on October 15, 2025. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of
About EyePoint
EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU™, is an innovative investigational sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor (TKI), in next-generation bioerodible Durasert E™ technology. Supported by robust safety and efficacy data across multiple clinical trials and indications, DURAVYU is currently being evaluated in two Phase 3 pivotal trials for wet age-related macular degeneration (wet AMD) with data anticipated in mid-2026. First patient dosing in the pivotal Phase 3 clinical trials in diabetic macular edema (DME) is expected in the first quarter of 2026.
The Company is committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Vorolanib is licensed to EyePoint exclusively by Equinox Sciences, a Betta Pharmaceuticals affiliate, for the localized treatment of all ophthalmic diseases outside of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally accepted by the FDA as the proprietary name for EYP-1901. DURAVYU is an investigational product; it has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
For EyePoint:
Investors:
Tanner Kaufman / Jenni Lu
FTI Consulting
Direct: 203-722-8743 / 667-321-6018
Tanner.Kaufman@fticonsulting.com / jenni.lu@fticonsulting.com
Media Contact:
Amy Phillips
Green Room Communications
Direct: 412-327-9499
aphillips@greenroompr.com
FAQ
What inducement awards did EyePoint (EYPT) grant on October 15, 2025?
What is the exercise price and term for the EYPT inducement options granted October 15, 2025?
How do the EyePoint (EYPT) inducement options vest?
Why were these stock options granted outside EyePoint's 2023 LTIP?
Who approved the EyePoint (EYPT) inducement option grants?
